Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ME 23andMe > Key Indicators
ME 23andMe
3.020
-0.170-5.33%
Pre Mkt Price
3.0200.0000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/06/30(FY)2022/03/31(Q4)2022/03/31(Q3)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-143.18% -2.8832 -190.69% -39.6368 -190.69% -39.6368 -- 40.7349
Receivable Turnover(T)
65.81% 44.98 -5.63% 92.7804 -5.63% 92.7804 -- 11.0321
Inventory Turnover(T)
31.44% 11.1794 -19.77% 16.3199 -19.77% 16.3199 -- 7.5589
Fixed Assets Turnover(T)
17.13% 2.5387 20.49% 2.3701 20.49% 2.3701 -- 2.3707
Total Asset Rate(T)
2.42% 0.2759 -37.17% 0.339 -37.17% 0.339 -- 0.2119
ROIC
-24.28% -31.335% -- -86.984% -- -86.984% -- -20.494%
ROE
-21.93% -34.943% -- -135.915% -- -135.915% -- -22.364%
ROA
-31.56% -26.378% 33.24% -27.116% 33.24% -27.116% -- -17.529%
Efficiency Ratios
Profitability Ratios TTM
Gross Margin
-6.10% 46.087% 1.93% 48.896% 1.93% 48.896% -- 50.177%
Operating Margin
-46.37% -109.031% -23.12% -93.475% -23.12% -93.475% -- -96.868%
Net Margin
-28.45% -95.609% -6.26% -79.991% -6.26% -79.991% -- -82.703%
EBITDA Margin
-46.29% -0.9787% -24.01% -0.8386% -24.01% -0.8386% -- -0.8848%
R & D Expense Ratio
6.91% 71.130% 6.27% 69.650% 6.27% 69.650% -- 71.040%
Sales Expense Ratio
114.89% 40.400% 108.36% 36.900% 108.36% 36.900% -- 31.180%
Administration Expense Rate
10.85% 42.390% -11.88% 35.820% -11.88% 35.820% -- 43.960%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-30.16% 8.925% -- 8.576% -- 8.576% -- 8.410%
Total Assets to Common Equity
-13.00% 124.354% -- 125.819% -- 125.819% -- 127.585%
Debt to Asset Ratio
-27.92% 9.849% -- 9.426% -- 9.426% -- 9.125%
Current Ratio
-38.76% 4.067 52.31% 3.9271 52.31% 3.9271 -- 3.7308
Quick Ratio
-40.60% 3.7737 55.00% 3.6319 55.00% 3.6319 -- 3.396
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports. The company operates under the Consumer and Research Services segment, and the Therapeutics segment. The firm’s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.
CEO: Ms. Anne Wojcicki
Market: NASDAQ
Listing Date: 06/17/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist